Literature DB >> 3665899

In vitro and in vivo susceptibility of Borrelia burgdorferi.

V P Mursic1, B Wilske, G Schierz, M Holmburger, E Süss.   

Abstract

The antispirochetal activity in vitro and in vivo of several antibiotics against ten isolates of Borrelia burgdorferi from human spinal fluids and skin biopsies was determined. Borrelia burgdorferi was most susceptible in vitro to erythromycin, ceftriaxone and cefotaxime (MIC90: 0.06, 0.06, 0.12 mcg/ml respectively). Less activity was observed with tetracycline, amoxycillin and lincomycin (MIC90: 0.50 mcg/ml), imipenem and augmentin (MIC90: 0.25 mcg/ml), oxacillin (MIC90: 1 mcg/ml), ciprofloxacin (MIC90: 2 mcg/ml) and ofloxacin (MIC90: 4 mcg/ml). Penicillin G, normally regarded as appropriate treatment for Lyme disease, had an MIC90 of only 4 mcg/ml. With the exception of erythromycin, activity in vitro corresponded to the activity in vivo. Erythromycin, however, was less active in vivo, and penicillin G showed poor activity both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3665899     DOI: 10.1007/bf02013102

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  8 in total

1.  High-dose penicillin therapy in meningopolyneuritis Garin-Bujadoux-Bannwarth. Clinical and cerebrospinal fluid data.

Authors:  W Kristoferitsch; U Baumhackl; E Sluga; G Stanek; K Zeiler
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1987-02

2.  Repeated isolation of spirochetes from the cerebrospinal fluid of a patient with meningoradiculitis Bannwarth.

Authors:  V Preac Mursic; B Wilske; G Schierz; H W Pfister; K Einhäupl
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

3.  Treatment of Lyme disease.

Authors:  K Weber
Journal:  Ann Intern Med       Date:  1981-01       Impact factor: 25.391

4.  [Acrodermatitis chronica atrophicans--a borreliosis!].

Authors:  V Preac-Mursic; B Wilske; P Herzer; G Schierz; M Bauer
Journal:  Hautarzt       Date:  1985-12       Impact factor: 0.751

5.  Infection of Syrian hamsters with Lyme disease spirochetes.

Authors:  R C Johnson; N Marek; C Kodner
Journal:  J Clin Microbiol       Date:  1984-12       Impact factor: 5.948

6.  Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin.

Authors:  A C Steere; A R Pachner; S E Malawista
Journal:  Ann Intern Med       Date:  1983-12       Impact factor: 25.391

7.  Successful parenteral penicillin therapy of established Lyme arthritis.

Authors:  A C Steere; J Green; R T Schoen; E Taylor; G J Hutchinson; D W Rahn; S E Malawista
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

8.  European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility.

Authors:  V Preac-Mursic; B Wilske; G Schierz
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1986-12
  8 in total
  44 in total

1.  Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents.

Authors:  D A Jobe; N Rawal; R F Schell; S M Callister
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.

Authors:  R C Johnson; C B Kodner; P J Jurkovich; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Persistence of Borrelia burgdorferi and histopathological alterations in experimentally infected animals. A comparison with histopathological findings in human Lyme disease.

Authors:  V Preac Mursic; E Patsouris; B Wilske; S Reinhardt; B Gross; P Mehraein
Journal:  Infection       Date:  1990 Nov-Dec       Impact factor: 3.553

Review 4.  Lyme disease in paediatrics.

Authors:  B Cryan; D J Wright
Journal:  Arch Dis Child       Date:  1991-11       Impact factor: 3.791

5.  Isolation of Borrelia burgdorferi from a skin lesion in a patient with granuloma annulare.

Authors:  F Strle; V Preac-Mursic; E Ruzic; B Wilske; J Cimperman
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

6.  Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice.

Authors:  Charles Pavia; Mario A Inchiosa; Gary P Wormser
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 7.  Antibiotic treatment of animals infected with Borrelia burgdorferi.

Authors:  Gary P Wormser; Ira Schwartz
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

8.  Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

Authors:  V Preac-Mursic; B Wilske; G Schierz; E Süss; B Gross
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

9.  Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo.

Authors:  J Alder; M Mitten; K Jarvis; P Gupta; J Clement
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

10.  Persistent atrioventricular block in Lyme borreliosis.

Authors:  W Mayer; F X Kleber; B Wilske; V Preac-Mursic; W Maciejewski; H Sigl; E Holzer; W Doering
Journal:  Klin Wochenschr       Date:  1990-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.